ClinicalTrials.Veeva

Menu

Antineoplastic Drugs in Elderly Patients

S

Shandong University

Status

Enrolling

Conditions

Cancer

Treatments

Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)

Study type

Observational

Funder types

Other

Identifiers

NCT05467189
Elderly-Antineoplastic drugs

Details and patient eligibility

About

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

Enrollment

500 estimated patients

Sex

All

Ages

65 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be enrolled in the study:

  1. Age ≥65 years old;
  2. Diagnosed with cancer;
  3. Using antineoplastic drugs for treatment.

Exclusion criteria

Subjects with any of the following criteria will not be enrolled in this study:

  1. Patients who are expected to die within 48 hours;
  2. Patients with allergy to antineoplastic drugs;
  3. Patients receiving other investigational drugs;
  4. Other factors that the researcher considers unsuitable for inclusion.

Trial design

500 participants in 1 patient group

treatment
Description:
The use of antineoplastic agents depends on the clinical practice.
Treatment:
Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)

Trial contacts and locations

1

Loading...

Central trial contact

Zhao Wei, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems